Management of Suspected Acute Coronary Syndrome

Initial Assessment and Management

The European Society of Cardiology recommends immediate evaluation and management for acute coronary syndrome (ACS), specifically ST-elevation myocardial infarction (STEMI) or high-risk non-STEMI, given the presentation of chest pain, positive cardiac biomarkers, cardiomegaly, hypotension, and tachycardia 1
The American Heart Association suggests that the ECG findings are essential to determine if this is STEMI requiring immediate reperfusion therapy (within 12 hours of symptom onset) versus NSTEMI/unstable angina 1
Look specifically for: persistent ST-segment elevation, new or presumed new left bundle-branch block, or ST-segment depression with T-wave changes suggesting posterior infarction 1

The European Heart Journal recommends assessing for Type 1 vs Type 2 Myocardial Infarction, with Type 1 MI (atherosclerotic plaque rupture) requiring coronary angiography and revascularization 1, 2
Type 2 MI (supply-demand mismatch) may be caused by tachycardia with relative hypotension, and marked troponin elevations may indicate severe respiratory failure, shock, or myocarditis in the context of systemic illness 2, 3

The European Society of Cardiology recommends administering intravenous morphine 4-8 mg with additional 2 mg doses at 5-15 minute intervals until pain relief, and giving antiemetics (metoclopramide 5-10 mg IV) concurrently 1
Administer oxygen 2-4 L/min by mask or nasal prongs for breathlessness or hemodynamic instability, and monitor blood oxygen saturation continuously 1
If STEMI is confirmed on ECG, early mechanical reperfusion (primary PCI) or pharmacological reperfusion should be performed immediately 1

The European Heart Journal recommends evaluating for tuberculous pericarditis given the history of pulmonary TB and cardiomegaly on chest X-ray, and performing urgent echocardiography to assess for pericardial effusion, cardiac tamponade, and regional wall motion abnormalities 4, 5
If cardiac tamponade is present, therapeutic pericardiocentesis is absolutely indicated 4, 5

The American Thoracic Society recommends continuing anti-tuberculosis therapy unless severe hepatotoxicity or drug interactions necessitate modification, with a standard regimen of rifampin, isoniazid, pyrazinamide, and ethambutol for 2 months, followed by isoniazid and rifampin for 4 months 6, 7
Monitor for drug-induced hepatitis, defined as AST >3x upper limit of normal with symptoms, or >5x without symptoms, and stop isoniazid, rifampin, and pyrazinamide immediately if hepatitis occurs 6

The European Heart Journal recommends combined troponin and CK-MB elevation as a significant predictor of mortality risk, with a 6-fold increase in death rate in non-MI patients 3

Do not attribute all symptoms to tuberculosis or anxiety without thoroughly excluding acute coronary syndrome, and do not delay reperfusion therapy waiting for troponin results if ECG shows STEMI 3, 1
Do not miss cardiac tamponade in a TB patient presenting with hypotension and cardiomegaly, and do not discontinue anti-tuberculosis therapy without clear indication 4, 5, 7, 9